<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701775</url>
  </required_header>
  <id_info>
    <org_study_id>2018/60-26</org_study_id>
    <nct_id>NCT04701775</nct_id>
  </id_info>
  <brief_title>Effect of Different Probiotic Strains in Hypercholesterolemic Patients</brief_title>
  <official_title>A Randomized Double-Blind Controlled Trial of Lactobacillus Acidophilus Plus Bifidobacterium Animalis Subsp.Lactis, Versus Lactobacillus Rhamnosus GG Versus Placebo in Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Mediterranean University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Mediterranean University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regular probiotic use for 8 weeks was evaluated in individual with mild to moderate&#xD;
      hyperlipidemia. Current study have been determined the use of different probiotics strains on&#xD;
      lipid parameters such as; total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride&#xD;
      levels as well as glycemic parameters such as; glucose, insulin, HOMA-IR levels. Also, hs-CRP&#xD;
      levels were investigated as inflammatory parameter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the light of recent studies, it has been shown that probiotics may have positive effects&#xD;
      on hyperlipidemia. The aim of this study was to investigate the effect of probiotics mainly&#xD;
      on blood lipids as well as homocysteine levels, glycemic control parameters and hs-CRP levels&#xD;
      A randomized, double-blind placebo-controlled study was completed with a total of 51&#xD;
      individuals who have diagnosed with hyperlipidemia. Participants were randomly assigned into&#xD;
      3 groups according to the probiotic type they would consume, groups were as follows;&#xD;
      Lactobacillus (probiotic group I) (n=18), Lactobacillus and Bifidobacterium (probiotic group&#xD;
      II) (n=17) and placebo group (n= 16). They were all requested to have placebo or probiotic&#xD;
      capsules every day for 8 weeks. Total cholesterol, HDL cholesterol, LDL cholesterol,&#xD;
      triglyceride levels were investigated as lipid metabolism parameters while fasting blood&#xD;
      glucose, insulin, HOMA-IR levels were investigated as glycemic parameters. Also, hs-CRP&#xD;
      levels were investigated as inflammatory parameter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Actual">March 7, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in total cholesterol level with the use of combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis decreases total cholesterol level. Change = (Baseline total cholesterol-Week 8 total cholesterol)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Low Density Lipoprotein (LDL) levels with the use of combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis decreases LDL cholesterol. Change = (Baseline LDL cholesterol values -Week 8 LDL cholesterol values)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Triglyceride levels with the use of combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis decreases triglyceride levels. Change = (Baseline triglyceride values -Week 8 triglyceride values)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in fasting glucose levels with the use of combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis decreases fasting blood glucose levels. Change = (Baseline fasting glucose values -Week 8 fasting glucose values)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in fasting insulin levels with the use of combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis decreases fasting insulin levels. Change = (Baseline fasting insulin values -Week 8 fasting insulin values)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total cholesterol level with the use of only Lactobacillus rhamnosus GG microorganism capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus rhamnosus GG microorganisms decreases total cholesterol level. Change = (Baseline total cholesterol-Week 8 total cholesterol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LDL cholesterol level with the use of only Lactobacillus rhamnosus GG microorganism capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus rhamnosus GG microorganisms decreases LDL cholesterol level. Change = (Baseline LDL cholesterol-Week 8 LDL cholesterol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in triglyceride level with the use of only Lactobacillus rhamnosus GG microorganism capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus rhamnosus GG microorganisms decreases triglyceride level. Change = (Baseline triglyceride values-Week 8 trgylceride values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting glucose level with the use of only Lactobacillus rhamnosus GG microorganism capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus rhamnosus GG microorganisms decreases fasting glucosel level. Change = (Baseline fasting glucosel-Week 8 fasting glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting insulin with the use of only Lactobacillus rhamnosus GG microorganism capsules at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Lactobacillus rhamnosus GG microorganisms decreases fasting insulin level. Change = (Baseline fasting insulin-Week 8 fasting insulin)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in total cholesterol level with the use of placebo at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Placebo capsules usually do not improve total cholesterol. Change = (Baseline total cholesterol values - Week 8 total cholesterol values)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in LDL cholesterol level with the use of placebo at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Placebo capsules usually do not improve LDL cholesterol. Change = (Baseline LDL cholesterol values - Week 8 LDL cholesterol values)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in triglyceride level with the use of placebo at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Placebo capsules usually do not improve triglyceride levels. Change = (Baseline triglyceride values - Week 8 total triglyceride values)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in fasting glucose level with the use of placebo at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Placebo capsules usually do not improve fasting glucose levels. Change = (Baseline fasting glucose values - Week 8 total fasting glucose values)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in fasting insulin level with the use of placebo at week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Placebo capsules usually do not improve fasting insulin levels. Change = (Baseline fasting insulin values - Week 8 fasting insulin values)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Lactobacillus rhamnosus GG Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received only 1x106 cfu Lactobacillus rhamnosus GG once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants recevied a combined Lactobacillus acidophilus 1x109 cfu and Bifidobacterium animalis subsp.lactis 1x109 cfu once a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Those participants received placebo capsule once a day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Only Lactobacillus rhamnosus GG strains</intervention_name>
    <description>1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule</description>
    <arm_group_label>Lactobacillus rhamnosus GG Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains</intervention_name>
    <description>combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule</description>
    <arm_group_label>Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo probiotic capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Had a repeated total cholesterol level ≥200 mg/dL prior to allocate to the study group&#xD;
        and to declined conventional lipid lowering medical treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those with any chronic conditions other than hypercholesterolemia,&#xD;
&#xD;
          -  Individuals with inherited lipid metabolic disorders,&#xD;
&#xD;
          -  Individuals with chronic gastrointestinal disease,&#xD;
&#xD;
          -  Individuals with immunodeficiency,&#xD;
&#xD;
          -  Individuals with malignancy,&#xD;
&#xD;
          -  Individuals with mental disabilities,&#xD;
&#xD;
          -  Patients currently using any lipid lowering drugs, or an alternative treatment to&#xD;
             lower blood cholesterol (such as probiotics) and individuals who have used antibiotics&#xD;
             in the previous three months prior to study and&#xD;
&#xD;
          -  Pregnant or lactating women were excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gözde Okburan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Medittanean University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gözde Okburan</name>
      <address>
        <city>Famagusta</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cyprus</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Mediterranean University</investigator_affiliation>
    <investigator_full_name>Gözde Okburan</investigator_full_name>
    <investigator_title>Assistant. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>serum lipids</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

